Serine protease inhibitor which displays weak inhibitory activity against trypsin (By similarity). May play a role in facial patterning during embryonic development (PubMed:26385749). First expressed the mesoderm of the emerging dorsal pancreatic bud at stage 17-18. Also expressed in the thyroid anlagen. Expression persists throughout the dorsal pancreatic mesoderm through E6 as the pancreas continues to enlarge. After E6, the amount of mesoderm in the pancreas declines to a minimal level and little or no expression is seen. The expression in the mesoderm of the thyroid persists at least through E8 in the development of this organ. Weakly expressed within the emerging lung buds and developing gut. Also expressed in developing carniofacial structures. At stage 17, expression is restricted to the cranial paraxial mesoderm. At stage 24, expressed in the corners of the frontonasal mass (globular processes) where the lip will fuse. At stage 26 through 29, becomes focused in the center of the frontonasal mass. At stage 30, further restricted to the future egg tooth. By stage 34, found in the egg tooth and structures derived from the frontonasal mass, such as the premaxillary mesenchyme (PubMed:26385749). Up-regulated by Noggin/NOG and retinoic acid. May be a direct retinoic acid target. Was named SugarCrisp after the breakfast cereal. Belongs to the CRISP family.